Know Labs Announces Laboratory Comparison Tests of its Non-Invasive Blood Glucose Technology and the DexCom G5®

Aug. 7, 2018 13:00 UTC

SEATTLE--(BUSINESS WIRE)-- Know Labs, Inc. (OTCQB: KNWN) – a provider of identification, authentication and diagnostic solutions, released today a video overview of comparison tests of the Company’s invention of a new way to detect blood glucose non-invasively and the DexCom G5®. In the video, Company CEO Phil Bosua discusses the breakthrough and highlights a comparison of the Know Labs Bio-RFID™ technology with an industry leading continuous glucose monitor from DexCom, Inc. (DXCM).

The transcript of Phil Bosua’s narrative in the video states in part:

“We’ve just invented a holy grail of the bio-tech industry – non-invasive – blood glucose monitoring. Our prototype sensor can detect blood glucose levels, but not with finger pricks – it’s completely non-invasive and we're super excited about this discovery and will be sharing more about how it works.

“This technology will help millions of people around the world, so we’re hard at work getting this to the next stage as fast as possible.”

Link to video: https://www.youtube.com/watch?v=hGqVGS5bKCI

Know Labs, Inc. is not affiliated with DexCom, Inc. DexCom G5® is a registered trademark of Dexcom, Inc.

About Know Labs, Inc.

Know Labs, Inc. (f/k/a Visualant Incorporated) is a public company whose shares currently trade under the stock symbol “KNWN.” The company’s technology directs structured light or radio waves through a substance or material to capture a unique molecular signature. The Company refers to these signatures as ChromaID™ and Bio-RFID™. ChromaID and Bio-RFID are used to identify, detect, or diagnose substance markers or biomarkers that may be invisible to the human eye. ChromaID and Bio-RFID scanner modules can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent pending, award-winning technology makes it possible to effectively conduct analyses that could only previously be performed by invasive and/or large and expensive lab-based tests. For more information on Know Labs, visit the company’s website at www.knowlabs.co.

 

Contacts

Know Labs, Inc.
Ron Erickson, 206-321-0721
ron@knowlabs.co

 

 
 

Source: Know Labs, Inc.

Back to news